MRK vs QDEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
QuidelOrtho exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a technical trend score of 0/100. Despite appearing 'cheap' on a Price-to-Book (0.45) and Price-to-Sales (0.32) basis, the company suffers from negative profit margins (-41.45%) and a catastrophic 5-year price decline of 89.6%. The disconnect between the bullish analyst target ($30.83) and the deteriorating fundamental health suggests a classic value trap. The lack of revenue growth (2.2%) and negative ROE (-46.15%) further undermine any recovery thesis.
Compare Another Pair
Related Comparisons
MRK vs QDEL: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and QuidelOrtho Corporation (QDEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.